Nizatidine: Difference between revisions
No edit summary Tag: nowiki added |
|||
| Line 70: | Line 70: | ||
Nizatidine was developed by [[Eli Lilly and Company|Eli Lilly]], and was first marketed in 1987. It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]] ring in place of the [[furan]] ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to [[Reliant Pharmaceuticals]].<ref name="encyclopedia">[http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 ]{{dead link|date=October 2015}}</ref> Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA).<ref name="reliant2004">[http://www.reliantrx.com/investor/press_releases/072604.htm]{{dead link|date=October 2015}}</ref> However, a year later, they sold rights of the Axid Oral Solution (including the issued patent<ref>{{cite web|url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6930119.PN.&OS=PN/6930119&RS=PN/6930119 |title=United States Patent: 6930119 |publisher=Patft.uspto.gov |date= |accessdate=2015-10-11}}</ref> protecting the product) to Braintree Laboratories.<ref name="reliant2005">[http://www.reliantrx.com/investor/press_releases/063005.htm]{{dead link|date=October 2015}}</ref> |
Nizatidine was developed by [[Eli Lilly and Company|Eli Lilly]], and was first marketed in 1987. It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]] ring in place of the [[furan]] ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to [[Reliant Pharmaceuticals]].<ref name="encyclopedia">[http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 ]{{dead link|date=October 2015}}</ref> Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA).<ref name="reliant2004">[http://www.reliantrx.com/investor/press_releases/072604.htm]{{dead link|date=October 2015}}</ref> However, a year later, they sold rights of the Axid Oral Solution (including the issued patent<ref>{{cite web|url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6930119.PN.&OS=PN/6930119&RS=PN/6930119 |title=United States Patent: 6930119 |publisher=Patft.uspto.gov |date= |accessdate=2015-10-11}}</ref> protecting the product) to Braintree Laboratories.<ref name="reliant2005">[http://www.reliantrx.com/investor/press_releases/063005.htm]{{dead link|date=October 2015}}</ref> |
||
Nizatidine proved to be the last new histamine H<sub>2</sub> |
Nizatidine proved to be the last new histamine H<sub>2</sub> receptor antagonist introduced prior to the advent of [[proton pump inhibitor]]s.{{cn}} |
||
==See also== |
==See also== |
||
Revision as of 10:10, 8 January 2016
 | |
| Clinical data | |
|---|---|
| Trade names | Axid |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a694030 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | >70% |
| Protein binding | 35% |
| Metabolism | Hepatic |
| Elimination half-life | 1–2 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.155.683 |
| Chemical and physical data | |
| Formula | C12H21N5O2S2 |
| Molar mass | 331.46 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.
Clinical use
Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.[1]
Adverse effects
Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[1]
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.[2] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).[3] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent[4] protecting the product) to Braintree Laboratories.[5]
Nizatidine proved to be the last new histamine H2 receptor antagonist introduced prior to the advent of proton pump inhibitors.[citation needed]
See also
- Famotidine (Pepcid) — another popular H2 receptor antagonist